Bladder Cancer Clinical Trial

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Summary

This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response.

This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.

View Eligibility Criteria

Eligibility Criteria

Abbreviated Inclusion Criteria:

Age 18 years or older, is willing and able to provide informed consent
Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types
Life expectancy > 12 weeks
ECOG performance status of 0-1

Abbreviated Exclusion Criteria:

History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.
Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study
Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy
History of severe autoimmune disease
Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

185

Study ID:

NCT04306900

Recruitment Status:

Active, not recruiting

Sponsor:

Trishula Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 32 Locations for this study

See Locations Near You

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

185

Study ID:

NCT04306900

Recruitment Status:

Active, not recruiting

Sponsor:


Trishula Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.